Compound Evidence File
#EC-2026-0426
4-Piperidone monohydrate hydrochloride CAS 40064-34-4
Filed under Raw Materials. The bureau holds 115 laboratory returns for this compound from 35 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
35 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 8 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 10.0 | 10.0 | 28 Mar 2026 | 18 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Feb 2026 | 3 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 27 Nov 2025 | 7 May 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Jan 2026 | 1 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 27 Jan 2026 | 15 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Jun 2026 | 23 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Jan 2026 | 11 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Jan 2026 | 23 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 28 Jul 2026 | 4 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Jan 2026 | 22 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 7 Feb 2026 | 21 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Feb 2026 | 16 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 27 Nov 2025 | 12 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Mar 2026 | 8 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 5 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 9.9 | 9.9 | 10.0 | 7 Nov 2025 | 1 Apr 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 9.9 | 20 Apr 2026 | 20 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Dec 2025 | 3 Jan 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 12 Apr 2026 | 1 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 19 Apr 2026 | 2 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Jun 2026 | 26 Jun 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 9.2 | 9.2 | 9.2 | 13 Feb 2025 | 13 Feb 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.4 | 7.5 | 9.5 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.2 | 7.1 | 9.5 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.2 | 7.4 | 8.7 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 7.8 | 7.4 | 9.5 | 24 May 2026 | 24 May 2026 |
| UtherCASE #VI-2026-0902 | X | 5 | 7.5 | 5.4 | 10.0 | 13 Feb 2025 | 26 Jan 2026 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 2 | 7.4 | 6.7 | 8.2 | 11 Jun 2025 | 19 Jan 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 6.9 | 6.0 | 7.2 | 23 May 2026 | 23 May 2026 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 6.5 | 6.5 | 6.5 | 8 Jul 2025 | 8 Jul 2025 |
| Amino AmigosCASE #VI-2026-0061 | X | 2 | 6.4 | 5.8 | 7.0 | 27 Feb 2025 | 25 May 2026 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 6.3 | 6.3 | 6.3 | 20 Jun 2025 | 20 Jun 2025 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 0.2 | 0.2 | 0.2 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for 4-Piperidone monohydrate hydrochloride CAS 40064-34-4 alone.